Roberto Borea, MD
@RobertoBoreaMD
Followers
401
Following
2K
Statuses
183
Medical Oncologist 🇮🇹| PhD student at @UniGenova | Focusing on translational research 🔎🧬 | ISLB YC member
Joined March 2022
⏱️ To-do list for today: Tune in to the live webinar by @IASLC covering key highlights from the 2024 Hot Topic in Basic & Translational Science Conference! 🔬🧬 Don't miss out on the latest breakthroughs! #LungCancer
@ChristianRolfo @rolfolab @triparnasen @HendriksLizza
🔬 Join the IASLC for a LIVE webinar on #NSCLC breakthroughs tomorrow! Experts will cover TKI resistance mechanisms, ADCs, & #SCLC transformation with insights from the 2024 Hot Topic Conference. Register now! 🔗 #TKIResistance #LungCancer #Oncology
0
3
8
Brilliant presentation by @ChristianRolfo from @OSUCCC_James talking about #precisiononcology in #lungcancer at #ESMOdeepdive 🔎 @myESMO @rolfolab
0
4
11
Don't miss the chance to dive into this interesting discussion on lung cancer with an incredible faculty! 🔎🫁💊 @myESMO @ChristianRolfo @rolfolab @CelineMascaux @TommyJohn00 @RaqPerezLopez
#lungcancer #precisiononcology
👉 The upcoming #ESMODeepDiveLung will delve into the latest advancements in the management of #LungCancer featuring leading experts in the field. Join with your ESMO membership now! 🔗
1
7
20
🚨 Share your expertise in the liquid biopsy field! 🌟 Participate in the @isliquidbiopsy survey to help shape strategies for improving #liquidbiopsies in clinical oncology. Let’s advance precision care for medical oncologists together! 🩺🔬
Survey Participation Request on Behalf of @isliquidbiopsy & @OncoAlert Oncologist Attitudes and Practices on Liquid Biopsy 👉 This survey aims to evaluate oncologists' attitudes, practices, and barriers to the use of liquid biopsy in clinical care. Your participation in this survey is voluntary. 10-15 minutes in length. @ChristianRolfo
@UmbertoMalapel1
@drgandara
@DrYukselUrun
@CtcLaboratory
@mayoccc
@HeekeSimon
@ElJanLe
@MJOSESERRANO19
@LuisRaezMD
@aadel_chaudhuri
@ReduzziCarol
@rolfolab
@WeOncologists
@RobertoBoreaMD
@eleonora_nicolo
@AngeloDipa_
@ESaldanhaMD
@A_OrtegaFranco
@GeorgieDibs
@ddemiguelperez
@mgoudaMD
@RoisinDaly__
@KonVenetis
@PasqualePisapia
0
5
8
Congratulations @boutrosand 💥
Thanks @MelanomaAus & @ProfGLongMIA for this incredible experience 🏖️
1
0
2
RT @isliquidbiopsy: 📌Our Scientific Secretary, Umberto Malapelle at the European Parliament, collaborating with Cancer Patient Europe and E…
0
15
0
RT @tactics_md: 🔵 Es el turno para escuchar las experiencias internacionales en #BiopsiaLíquida Interviene el Dr. Umberto Malapelle (@Umbe…
0
8
0
RT @pmmpitalia: 📢 Save the Date! 🗓️ L'XI Incontro Nazionale PMMP è in arrivo! 🔬🧬 📍 Firenze - Palazzo degli Affari 📅 11-12 aprile 2025 Unis…
0
4
0
RT @HHorinouchi: 🔥@NatureMedicine🆙 ✅NeXT Personal: Ultrasensitive ctDNA detection for preope early-stage lung adenocarcinoma 🎯Whole-genome,…
0
25
0
RT @JAMAOnc: Quitting smoking within 6 months of a cancer diagnosis improves survival outcomes, with the greatest benefits observed in thos…
0
72
0
RT @isliquidbiopsy: 🧬✨ ISLB Research Highlight! ✨🧬 ctDNA and Beyond to Serve Immunotherapy 🔍 Key Insights from #ESMOImmuno24: ✅Stable blo…
0
14
0
RT @StephenVLiu: Phase II study of osimertinib in pts with #EGFR NSCLC and PS 2-4 (OPEN/TORG2040) @JTOonline (n=30). Here, RR 63.3%, DCR 93…
0
23
0
RT @isliquidbiopsy: Clinical Characteristics of EGFR-ctDNA Shedders in EGFR-Mutant NSCLC Patients 🔍 Key Takeaways: ✅EGFR-ctDNA sh…
0
13
0
RT @rolfolab: 🚨our paper open access “Clinical characteristics of EGFR-ctDNA shedders in EGFR-mutant NSCLC patients” great collaboration w…
0
11
0
RT @isliquidbiopsy: Prenatal cfDNA Sequencing and Incidental Detection of Maternal Cancer 🔍 Key Findings: ✅48.6% of participants with unu…
0
12
0
RT @Lucarecco: Proud of our super @UniGenova resident @nardin_simone for this analysis on the suboptimal #OFS among the PREFER and GIM stud…
0
6
0
0
4
0
RT @Lucarecco: Other crucial evidences from the 🌍 BRCA BCY study Presented at #SABCS24 by @matteolambe the role of RRM and RRSO in young p…
0
18
0
RT @nardin_simone: Astonishing presentation by @matteolambe on the impact of risk-reducing mastectomy and risk-reducing salpingo-oophorecto…
0
4
0
RT @Lucarecco: Updated results from #OlympiA trial presented by @judygarber5 in GS1 at #SABCS24 Maintained benefit of adjuvant Olaparib in…
0
17
0